Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes

Journal of the American College of Cardiology

Volumn 61, Issue 2, 2013, Pages 148-152

  Waters, David D ^a   Ho, Jennifer E ^b   Boekholdt, S Matthijs ^c   Demicco, David A ^d   Kastelein, John J P ^c   Messig, Michael ^d   Breazna, Andrei ^d   Pedersen, Terje R ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d PFIZER INC   (United States)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

atorvastatin; cardiovascular events; diabetes; statins

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EVENT; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART ARREST; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART ARREST; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRROLES; RISK FACTORS; SIMVASTATIN; STROKE;

EID: 84871921229     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.09.042     Document Type: Article

References (23)

1. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. N. Sattar, D. Preiss, H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
4. D. Preiss, S.R. Seshasai, P. Welsh Risk of incident diabetes with intensive-dose compared to moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
5. D.D. Waters, J.E. Ho, D.A. DeMicco Predictors of new-onset diabetes in patients treated with atorvastatin Results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
6. P.W.F. Wilson, J.B. Meigs, L. Sullivan, C.S. Fox, D.M. Nathan, R.B. D'Agostino Prediction of diabetes mellitus in middle-aged adults The Framingham Offspring study Arch Intern Med 167 2007 1068 1074
7. M. Rahman, R.K. Simmons, R.H. Harding, N.J. Wareham, S.J. Griffin A simple risk score identifies individuals at high risk of developing type 2 diabetes: a prospective cohort study Fam Pract 25 2008 191 196
8. A.M. Kanaya, C.L. Wassel Fyr, N. de Rekeneire Predicting the development of diabetes in older adults The derivation and validation of a prediction rule Diabetes Care 28 2005 404 408
9. D.D. Waters, J.R. Guyton, D.M. Herrington Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93 2004 154 158
10. J.C. LaRosa, S.M. Grundy, D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
11. T.R. Pedersen, O. Faergeman, J.J.K. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction JAMA 294 2005 2437 2445
12. D.J. Freeman, J. Norrie, N. Sattar Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention study Circulation 103 2001 357 362
13. M.J. Tikkanen, M. Szarek, R. Fayyad Total cardiovascular disease burden: comparing intensive with moderate statin therapy J Am Coll Cardiol 54 2009 2353 2357
14. J. Shepherd, P. Barter, R. Carmena Effect of lowering LDL cholesterol substantially below the currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 29 2006 1220 1226
15. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
16. P. Deedwania, P. Barter, R. Carmena Reduction in low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Lancet 368 2006 919 928
17. A.P. Kengne, A. Patel, M. Marre Contemporary model for cardiovascular risk prediction in people with type 2 diabetes Eur J Cardiovasc Prev Rehabil 18 2011 393 398
18. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
19. K.L. Wang, C.J. Liu, T.F. Chao Statins, risk of diabetes, and implications on outcomes in the general population J Am Coll Cardiol 60 2012 1231 1238
20. M. Nakata, S. Nagasaka, I. Kusaka, H. Matsuoka, S. Ishibashi, T. Yada Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control Diabetologia 49 2006 1881 1892
21. H. Sato, G. Carvalho, T. Sato Statin intake is associated with decreased insulin sensitivity during cardiac surgery Diabetes Care 35 2012 2095 2099
22. T. Takano, T. Yamakawa, M. Takahashi, M. Kimura, A. Okamura Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus J Atheroscler Thromb 13 2006 95 100
23. T. Mita, H. Watada, S. Nakayama Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia Endocr J 54 2007 441 447